Ajanta Pharma launches asthma drug in the US

Ajanta Pharma announces the launch of Montelukast Sodium Oral Granules

id-100112438-1

Ajanta's drug is a bioequivalent generic version of SINGULAIR Granules

Ajanta Pharma USA, a subsidiary of Ajanta Pharma has announced the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market. Ajanta Pharma offers Montelukast Granules in cartons containing 30 individual sachets.

The approval and launch of the Montelukast Granules is part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. To date, the United States Food and Drug Administration (US FDA) has granted Ajanta Pharma five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA.

SINGULAIR is a registered trademark of Merck and Co., Inc.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X